Navigation Links
In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
Date:3/18/2009

Telaprevir in Combination with a Long-Acting Interferon and Ribavirin Will Earn Decision Resources' Clinical Gold Standard for Hepatitis C Virus in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists and hepatologists identify a therapy's effect on sustained virologic response in genotype 1 patients as the attribute that most influences their prescribing decisions in hepatitis C virus infection. Clinical data and the opinions of interviewed thought leaders indicate that the addition of Vertex/Janssen Pharmaceutica/Mitsubishi Tanabe's telaprevir or Schering-Plough's boceprevir to peginterferon/ribavirin provide advantages in this attribute over Roche's Pegasys (peginterferon-a-2a) plus ribavirin, the sales-leading treatment in the market.

The new report entitled Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment finds that a novel protease inhibitor that, when used in combination with peginterferon/ribavirin and achieves a significantly higher sustained virologic response in genotype 1 patients with only 24 weeks of treatment compared with the standard 48-week therapy with peginterferon/ribavirin, would earn a higher patient share in the United States than in Europe. The report finds that such an agent would earn a 60 percent patient share in the U.S. and a 40 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists and hepatologists.

In 2008, Decision Resources' proprietary clinical gold standard for hepatitis C virus was Pegasys plus ribavirin because of its advantages in delivery and dosing. Based on available data and expert opinion, telaprevir plus ribavirin and a long-acting interferon will earn gold-standard status for hepatitis C virus following approval of telaprevir in 2011.

"New regimens that include a protease inhibitor, such as telaprevir or boceprevir, appear to have a competitive advantage in efficacy in patients infected with genotype 1 over the current peginterferon/ribavirin regimens," said Decision Resources Vice President John Lebbos, M.D. "Furthermore, the duration of therapy for genotype 1 patients can potentially be reduced with new three-drug regimens."

About the Report

Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563
    ccomfort@dresources.com                  emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is telmisartan effective in treating non-alcoholic steatohepatitis?
2. Varicella zoster infection causes severe autoimmune hepatitis
3. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
4. Liver transplant recipients with hepatitis B may need lifelong antiviral treatment
5. Pitt receives $11 million from NIH to coordinate hepatitis B clinical research network
6. PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine
7. Hispanics Respond Poorly to Standard Hepatitis C Therapy
8. May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
9. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
10. Hepatitis C treatment reduces the virus but liver damage continues
11. Improved Testing for Hepatitis B Virus From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
Breaking Medicine Technology: